Rigel Pharmaceuticals | RIGL - Loan Capital


Rigel Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Agenus USD 153.98M 15.68M Mar/2026
Amgen USD 51.86B 27M Jun/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Daiichi Sankyo JPY 500B 199.92B Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 446.9M 704K Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60.5B 70M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Veracyte USD 0 0 Mar/2025